0
SAKATA INX CORPORATION (Yoshiaki Ueno, Representative Director, President & CEO) announces that it made a joint investment in Salus Lab Co., Ltd. (Headquarter: Sumiyoshi-ku, Osaka city, Representative Director: Isao Yuasa), which is a university-launched venture that aims to commercialize plant-derived functional materials. The venture is led by Professor Emeritus Isao Yuasa and Associate Professor Akiko Kojima of Osaka City University, Graduate School of Human Life Science.
With the theme to “reveal and conduct applied strategic research in life-style related disease prevention mechanism from dietary plant constituents and nutrient, ” Akiko Kojima’s Lab in Osaka City University conducts research on the structure of the human biological regulatory factor and its working mechanism. As one of their research developments, they showed findings of enhancement effect in the brain function from a component extracted from “Galangal” which is one of Zingiberaceae(A. Kojima-Yuasa, et al. Chemic-Biological Interactions 257: 101-109 (2016).
With a private company taking part in the newly established Salus Lab Co., Ltd., R&D-oriented venture, it will help to facilitate research. We aim to commercialize plant-derived functional materials with health-promoting effects in the future.
In order for us to “contribute to making people’s lives comfortable” stated in our long-term strategic vision, we decided to take part in commercialization of dietary plant constituents that is promising to maintain health and extend healthy life expectancy. We will advance business development so that we can contribute to establish a society where people can live true to themselves.
With the theme to “reveal and conduct applied strategic research in life-style related disease prevention mechanism from dietary plant constituents and nutrient, ” Akiko Kojima’s Lab in Osaka City University conducts research on the structure of the human biological regulatory factor and its working mechanism. As one of their research developments, they showed findings of enhancement effect in the brain function from a component extracted from “Galangal” which is one of Zingiberaceae(A. Kojima-Yuasa, et al. Chemic-Biological Interactions 257: 101-109 (2016).
With a private company taking part in the newly established Salus Lab Co., Ltd., R&D-oriented venture, it will help to facilitate research. We aim to commercialize plant-derived functional materials with health-promoting effects in the future.
In order for us to “contribute to making people’s lives comfortable” stated in our long-term strategic vision, we decided to take part in commercialization of dietary plant constituents that is promising to maintain health and extend healthy life expectancy. We will advance business development so that we can contribute to establish a society where people can live true to themselves.
◆Company description of Salus Lab Co., Ltd
Company Name | Salus Lab Co., Ltd. |
---|---|
Location | 3-3-138, Sugimoto, Sumiyoshi-ku, Osaka city, Osaka (Inside Osaka City University) |
Representative | Isao Yuasa |
Business Content | ・Research and development of health and beauty ・Commissioned Research and development ・Development, manufacture, sale, import and export of health products, supplements, organic food, cosmetics, food additives, health drinks, etc. ・Other businesses |
Capital | 9,900,000 yen |
Incorporated | January 26, 2022 |
Investor | SAKATA INX CORP., Konan Chemical Industry co., ltd., Isao Yuasa, Retex Research Lab Inc. |
Inquriy
-
Public & Investor Relations Div.